Primary Human Immunodeficiency Virus Type 1 Infection: Clinical Manifestations among Women in Mombasa, Kenya
|
|
- Laureen Shields
- 5 years ago
- Views:
Transcription
1 486 Primary Human Immunodeficiency Virus Type 1 Infection: Clinical Manifestations among Women in Mombasa, Kenya Ludo Lavreys, 1,2 Mary Lou Thompson, 1 Harold L. Martin, Jr., 1,a Kishorchandra Mandaliya, 3 Jeckoniah O. Ndinya-Achola, 2 Job J. Bwayo, 2 and Joan Kreiss 1 From the 1 Departments of Epidemiology, Medicine, and Biostatistics, University of Washington, Seattle, Washington; and 2 Department of Medical Microbiology, University of Nairobi, and 3 Coast Provincial General Hospital, Mombasa, Kenya The occurrence of clinical manifestations associated with primary human immunodeficiency virus type 1 (HIV-1) infection was evaluated in a prospective cohort study of female sex workers in Mombasa, Kenya. Among 103 women who seroconverted to HIV-1, fever, vomiting, diarrhea, headache, arthralgia, myalgia, skin rash, swollen lymph nodes, extrainguinal lymphadenopathy, inguinal lymphadenopathy, and vaginal candidiasis were noted significantly more frequently at visits in which seroconversion first became evident. Eighty-one percent of seroconverting women had 1 of these 11 symptoms or signs. Among 44% of the women, the acute illness was severe enough to prevent them from working. Having 2 of6 selected symptoms and signs yielded a sensitivity of 51%, specificity of 83%, positive likelihood ratio of 3.2, and negative likelihood ratio of 0.5 for acute HIV-1 infection. The recognition of primary HIV-1 infection illness in high-risk populations and subsequent risk-reduction counseling could potentially reduce secondary HIV-1 transmission during this highly infectious period. Acute HIV-1 infection often results in a symptomatic mononucleosis-like illness. The most frequently reported symptoms and signs include fever, fatigue, rash, headache, lymphadenopathy, pharyngitis, myalgia, arthralgia, and gastrointestinal problems [1]. The illness is self-limited, but it may last up to 4 weeks and sometimes is of sufficient severity to warrant hospitalization. Symptomatic illness corresponds with an early phase of high viral load, and resolution of symptoms occurs as the host immune response evolves and HIV-1 specific antibodies become detectable. The frequency of symptomatic primary HIV-1 infection is unknown [2]. Most published studies have been cross-sectional and have described clinical signs and symptoms among patients who came to medical attention. It has been estimated that 50% 90% of newly infected individuals are symptomatic, but this may be an overestimate, given the limitations of the study designs [1, 3]. In addition, the signs and symptoms that characterize primary HIV-1 infection are nonspecific, and few pub- Received 14 July 1999; revised 29 October 1999; electronically published 8 March Financial support: This project was supported by the National Institutes of Health through Family Health International (N01-AI ) and through grants AI-33873, D43-TW00007, and T22-TW Informed consent was obtained from all study participants, and the study was approved by the ethical review committees of the University of Washington and the University of Nairobi. a Current affiliation: Park Nicollet Clinic, Minneapolis, Minnesota. Reprints or correspondence: Dr. Joan Kreiss, University of Washington, Box , 325 Ninth Ave., Seattle, WA Clinical Infectious Diseases 2000;30: by the Infectious Diseases Society of America. All rights reserved /2000/ $03.00 lished studies have included a seronegative control group for comparison [4]. Comparing the frequency of signs and symptoms in both case and control patients would help determine their utility as screening tools for newly acquired HIV-1 infection. Data on acute HIV-1 illness from developing countries are scarce. In a nested case-control study, Bollinger et al. studied patients with sexually transmitted diseases (STDs) in Pune, India, and found that a positive p24 antigen test, suggesting recent infection with HIV-1, was significantly associated with a history of fever, joint pain, and night sweats, after adjustment for presence of STDs [5]. In Mombasa, Kenya, we initiated a prospective study of a cohort of HIV-1 seronegative female sex workers in 1993 as part of the Preparation for AIDS Vaccine Evaluation (PAVE)/ HIV Network for Prevention Trials (HIVNET) initiative, with the aims of determining HIV-1 seroincidence and correlates of seroconversion [6]. Over a 5-year period, clinical, behavioral, and laboratory data were prospectively collected, including data on symptoms and signs associated with acute HIV-1 illness, allowing comparison of their occurrence in seronegative and newly HIV-1 infected patients. Patients and Methods Study patients and procedures. Between March 1993 and March 1998, sex workers who attended Ganjoni Municipal Clinic in Mombasa were invited to enroll in a prospective cohort study, as described elsewhere [6]. Women underwent serological testing for HIV-1 after providing informed consent. HIV-1 seronegative women were enrolled in the cohort study.
2 CID 2000;30 (March) Primary HIV-1 Infection 487 At the enrollment visit, data were collected regarding demographic variables, sexual behavior, and medical history. Patients underwent a general physical examination, including pelvic examination, and STD screening. Study patients were then asked to return every month for follow-up. At each visit, a questionnaire on interim sexual behavior and medical history was administered, covering the period since the last clinic visit. Specifically, women were asked about possible symptoms of primary HIV-1 infection. A physical examination was performed, and clinical signs associated with primary HIV-1 infection were noted. STD screening was conducted, and a blood sample for HIV-1 serological testing was obtained. All women received risk-reduction counseling and a free supply of condoms. Women with an STD received appropriate treatment. Laboratory procedures. HIV-1 serological testing was performed with an ELISA (Detect-HIV; Biochem ImmunoSystem, Montreal). A second confirmatory ELISA (Recombigen; Cambridge Biotech, Worcester, MA) was performed if a sample tested positive on the screening ELISA. All HIV-1 seroconversions during follow-up were confirmed by HIV-1 Western blotting (Cambridge Biotech). Screening for Candida species was performed with vaginal-specimen wet mounts and KOH microscopy. Data analysis. Data were double-entered by use of SPSS software (SPSS, Chicago) and were verified by comparison of line listings with the clinic files. Data analysis was performed with SPSS statistical software and S-PLUS (MathSoft, Seattle). For purposes of analysis, records were censored after the time of documented HIV-1 seroconversion. Visits were included in the analysis if they occurred within 3 months of the preceding visit. A seroconversion visit was defined as the first visit at which the HIV-1 serological test became positive. The frequency of symptoms and signs during seroconversion and nonseroconversion visits was compared. ORs for the presence of symptoms and signs in seroconverters versus nonseroconverters were estimated by means of logistic regression models with generalized estimating equations, with adjustment for time since the last clinic visit because of the unequal intervals between visits. The use of generalized estimating equations adjusts for multiple visits by the same individual [7]. Symptoms and signs that were significantly associated with seroconversion visits in univariate analysis were entered in a multivariate logistic regression model, with HIV-1 status as outcome and with adjustment for time between clinic visits. Stepwise backward elimination was used to select the subset of signs and symptoms with P!.15. A scoring system was developed, with 1 point being assigned to each of these symptoms or signs. Sensitivity, specificity, and likelihood ratios were estimated from logistic regression modeling with generalized estimating equations. Confidence intervals for the likelihood ratios were calculated, as described by Simel et al. [8] and Dujardin et al. [9]. The positive and negative likelihood ratios represent how much more likely a test is to be positive or negative in diseased than in nondiseased individuals [9]. Results Study patients. From March 1993 through March 1998, 4007 women were screened for HIV-1 antibodies, and 53.5% were seropositive. One thousand fifty-three HIV-1 seronegative women were enrolled in the prospective cohort study, and 883 women returned for 1 follow-up visits. A total of 9851 followup clinic visits occurred over a 5-year period. The median follow-up time was 12 months, ranging from 1 to 60 months. One hundred sixty-two patients seroconverted during follow-up, yielding an annual HIV-1 infection incidence of 12% (162 seroconversions per 1353 person-years). Seven thousand seven hundred and thirty-five follow-up visits by 823 women occurred within 3 months of the previous clinic visit and were therefore eligible for analysis. This subset included 103 seroconversion visits. The median time between the last seronegative visit and the first seropositive visit was 1.1 months, ranging from 1 week to 3 months. For the participants included in this analysis, median age at enrollment was 26 years (range, years), and only 1% of women were married. The median duration of education was 8 years (range, 0 18 years). Age at first sexual contact was 16 years (range, 7 28 years). At enrollment, the median duration of prostitution was 1 year (range, 0 24 years). The median frequency of sexual acts per week was 2 (range, 0 13), and the median number of different sex partners was 1 (range, 0 10). Twenty percent of the women smoked cigarettes, and 79% drank alcohol at least once per week. Frequency of signs and symptoms. The frequency of clinical symptoms reported by the women at seroconversion visits was significantly greater than that reported at nonseroconversion visits (table 1). Fever was the most common symptom and was reported by 53% of seroconverting women and 27% of nonseroconverting women (OR, 2.8; 95% CI, ). Other symptoms that were reported significantly more often at the seroconversion visit were vomiting (OR, 4.8; 95% CI, ), diarrhea (OR, 3.1; 95% CI, ), headache (OR, 2; 95% CI, 1.3 3), arthralgia (OR, 2.1; 95% CI, ), myalgia (OR, 2.8; 95% CI, ), skin rash (OR, 2.1; 95% CI, 1 4.2), and swollen lymph nodes (OR, 3.3; 95% CI, ). There were trends toward an association between seroconversion visits and fatigue (OR, 1.6; 95% CI, 1 2.5) and pharyngitis (OR, 1.7; 95% CI, 1 3.1). On physical examination, extrainguinal lymphadenopathy (OR, 6.1; 95% CI, ), inguinal lymphadenopathy (OR, 9.5; 95% CI, ), and vaginal candidiasis (OR, 2.7; 95% CI, ) were observed more frequently at seroconversion visits than at nonseroconversion visits. There was also a trend toward higher frequency of cervical mucopus at seroconversion visits (OR, 2; 95% CI, 1 4.3). Oral thrush, oral hairy leukoplakia, conjunctivitis, maculopapular skin rash, and herpes zoster were seldom seen in this cohort. Eighty-three (81%) of the 103 seroconverting women had 1 of the 11 symptoms or signs that were significantly associated with acute HIV-1 infection, and 53 (52%) had 3 of these symptoms or signs. For comparison, women at 3836 (52%) of 7323 nonseroconverting visits had 1 of these 11 symptoms or
3 488 Lavreys et al. CID 2000;30 (March) Table 1. Clinical symptoms and signs in Kenyan women at the clinic visit when HIV-1 seroconversion was documented and at visits when they tested seronegative. Symptom or sign % (proportion) of patients at visit HIV-1 seroconversion HIV-1 seronegative Adjusted OR a (95% CI) Symptom Fever 53.4 (55/103) 26.6 (1958/7350) 2.8 ( )!.001 Vomiting 18.4 (19/103) 4.2 (311/7350) 4.8 ( )!.001 Diarrhea 16.5 (17/103) 5.7 (421/7350) 3.1 ( )!.001 Headache 43.7 (45/103) 24.7 (1817/7350) 2 (1.3 3)!.001 Fatigue 26.2 (27/103) 15.8 (1164/7350) 1.6 (1 2.5).05 Arthralgia 24.3 (25/103) 12.6 (925/7349) 2.1 ( ).002 Myalgia 18.4 (19/103) 7.6 (560/7350) 2.8 ( )!.001 Pharyngitis 14.6 (15/103) 7.9 (580/7350) 1.7 (1 3.1).05 Conjunctivitis 2.9 (3/103) 1.6 (116/7350) 1.9 ( ).3 Skin rash 8.7 (9/103) 4.3 (313/7350) 2.1 (1 4.2).04 Swollen lymph glands 6.8 (7/103) 2.1 (154/7350) 3.3 ( ).003 Too sick to work 43.7 (45/103) 14.7 (1077/7350) 4 ( )!.001 Sick days: 17 since last clinic 16.5 (17/103) 2.3 (172/7350) 7.4 ( )!.001 visit Sign Splenomegaly 1.9 (2/103) 0.5 (39/7623) 2.3 ( ).7 Extrainguinal lymphadenopathy b 2.9 (3/103) 0.5 (38/7623) 6.1 ( ).002 Inguinal lymphadenopathy b 2.9 (3/103) 0.3 (20/7624) 9.5 ( )!.001 Oral thrush 0 (0/103) 0 (1/7623) NA Oral hairy leukoplakia 0 (0/103) 0 (1/7623) NA Conjunctivitis 1 (1/103) 0 (2/7623) NA Maculopapular skin rash 0 (0/103) 0.2 (14/7623) NA Herpes zoster 0 (0/103) 0 (1/7623) NA Genital ulcers 2.9 (3/103) 1.2 (95/7616) 2.6 ( ).1 Genital warts 4.9 (5/103) 4.5 (344/7600) 0.9 ( ).8 Vaginal discharge 18.4 (19/103) 18.3 (1393/7623) 0.9 ( ).6 Vulvitis 5.1 (4/79) 3 (157/5200) 1.5 ( ).5 Cervical mucopus 8.9 (9/101) 3.9 (294/7543) 2 (1 4.3).06 Vaginal candidiasis 27.2 (28/103) 9.8 (746/7611) 2.7 ( )!.001 a Adjusted for the time between clinic visits. b Lymphadenopathy at 2 sites. signs ( P!.001), and 18% had 3 ( P!.001). Among seroconverters, these 8 symptoms and 3 signs occurred with the following decreasing order of frequency: fever (53%), headache (44%), arthralgia (24%), myalgia (18%), vomiting (18%), diarrhea (17%), skin rash (9%), and swollen lymph nodes (7%); and vaginal candidiasis (27%), extrainguinal lymphadenopathy (3%), and inguinal lymphadenopathy (3%). Acute HIV-1 infection symptoms were often of sufficient severity to prevent women from working. Forty-four percent of women at seroconversion visits reported having been too sick to work, compared with 15% at nonseroconversion visits (OR, 4; 95% CI, ). Women at seroconversion visits also reported longer duration of work absence than did those at nonseroconversion visits. Seventeen percent of the women at seroconversion visits stayed home for 11 week, compared with 2% of the women at nonseroconversion visits (OR, 7.4; 95% CI, ). Sensitivity, specificity, and likelihood ratios for symptoms and signs. A scoring system was developed, as described in the Methods, that included 4 symptoms (fever, vomiting, diarrhea, and too sick to work) and 2 clinical signs (inguinal lymphadenopathy and vaginal candidiasis). Sensitivity, specificity, and likelihood ratio were calculated, as shown in table 2. For a cutoff level of 2 symptoms or signs, the sensitivity for detecting primary HIV-1 infection was 51%, and the specificity was 83%. The positive likelihood ratio was 3.2, i.e., HIV-1 seroconverting women were 3 times more likely than nonseroconverting women to have 2 symptoms or signs. The corresponding negative likelihood ratio was 0.5, i.e., nonseroconverting women were twice as likely as seroconverting women to have a score!2. Discussion In this prospective cohort study of female sex workers, we identified 11 symptoms and signs that were significantly associated with HIV-1 seroconversion. Four-fifths of seroconverting women had 1 of these symptoms or signs of primary HIV-1 infection. For 44% of the seroconverters, the illness was severe enough to prevent working, and 17% were out of work for 11 week. To our knowledge, this is the first characterization of the clinical manifestations of HIV-1 infection in an African population. A major strength of this study was its prospective design. Monthly serological testing permitted identification of primary HIV-1 infections soon after the time of virus acquisition. Our P
4 CID 2000;30 (March) Primary HIV-1 Infection 489 Table 2. Sensitivity, specificity, and likelihood ratios for different cutoff levels of scores for symptoms and signs. Cutoff levels Sensitivity (%) Specificity (%) LR 95% CI LR 95% CI NOTE. Symptoms and signs included in this scoring system were fever, vomiting, diarrhea, too sick to work, inguinal lymphadenopathy, and vaginal candidiasis. LR, positive likelihood ratio; LR, negative likelihood ratio. estimate of the frequency of primary HIV-1 illness may therefore be more accurate than those in clinic- or hospital-based studies that identify seroconverting patients on the basis of presenting illness. A second related strength was the ability to compare seroconversion with nonseroconversion visits. This comparison revealed a relatively high prevalence of symptoms and signs in the seronegative control group, but illness in these women tended to be less severe. Only 15% of these women were too sick to work, and only a small fraction (2%) stayed home from work for 11 week. We examined the usefulness of a checklist of selected symptoms and signs as a means of identifying people with recent HIV-1 infection. In any screening procedure, there is a tradeoff between false-positives and false-negatives, since sensitivity and specificity are inversely related. At a higher positive likelihood ratio, seroconverters would be more likely to have symptoms and signs than nonseroconverters, but the sensitivity decreases, resulting in identification of fewer individuals with recent HIV-1 infection. The choice of a cutoff point in the scoring system depends on the consequences and costs of false-positives relative to falsenegatives and the prevalence of disease in the particular setting. This study population had a seroconversion-visit prevalence of 1.3%. If we selected a cutoff level of 2 in the checklist, sensitivity would be 51% and the specificity would be 83%, but the positive predictive value would be only 4%. In settings with a higher seroconversion-visit prevalence, the positive predictive value would increase. Because the sensitivity, specificity, and likelihood ratios are determined by the frequency of symptoms and signs during seropositive and seronegative visits, which may vary in different populations, our results cannot be extrapolated to all settings. Recognition of primary HIV-1 infection is important for several reasons. First, the severity of symptomatic illness is of prognostic significance with respect to natural history of HIV- 1 [10]. The plasma viral burden during acute HIV-1 infection or during the first year after seroconversion appears to establish the viral set point for the chronic phase of the disease [11, 12]. Second, the recognition of primary HIV-1 infection can prompt early initiation of antiretroviral therapy [13, 14]. Although clinical data are still limited, especially for long-term benefits, the Centers for Disease Control and Prevention and the International AIDS Society/USA Panel recommend that therapy should be initiated within 6 months of infection, before extensive immune system damage has occurred [15, 16]. Third, the study of primary HIV-1 infection can provide valuable information about the interaction of viral and host immunologic factors that may be of relevance for vaccine development [17]. Fourth, and most important from a public health perspective, identification and counseling of newly infected individuals may reduce transmission of HIV-1 during a period of increased infectivity. A substantial proportion of HIV-1 transmission overall is thought to be due to transmission from recently infected persons, because of transient high titers of cytopathic virus [2, 18]. Although the number of individuals with new HIV-1 infection is much smaller than the number of chronically infected individuals, the former contribute disproportionately to transmission [19]. Therefore, identification and counseling of recent seroconverters, with or without antiretroviral therapy, could have a marked effect upon the HIV-1 epidemic on a population level [20, 21]. In summary, in this cohort of women with high-risk behavior, HIV-1 seroconversion was accompanied by a high prevalence of symptoms and signs, consistent with acute HIV-1 illness. Although a number of the symptoms and signs were nonspecific, the occurrence of a constellation of characteristic clinical manifestations, particularly if of sufficient severity to prevent the patient from working, should alert a clinician to the possibility of primary HIV-1 infection and to offer HIV-1 testing. Although antiretroviral therapy is not available for the majority of newly infected HIV-1 individuals in Africa, detection of primary HIV-1 infection could lead to risk-reduction counseling to prevent secondary transmission to sexual partners or to infants. In settings in which the HIV-1 epidemic is rapidly expanding and many primary infections are occurring, identification of newly infected individuals and appropriate counseling could be an important public health intervention. Acknowledgments We thank Drs. Patrick Nyange (deceased), Salim Hassanali, Myra Maghasi, and Saade Abdalla; Claire Stevens; the staff of Ganjoni Clinic for their assistance with data collection; the Municipal Council of
5 490 Lavreys et al. CID 2000;30 (March) Mombasa for use of their facilities; and the women who participated in the study. References 1. Kahn J, Walker B. Acute human immunodeficiency type 1 infection. N Engl J Med 1998;339: Clark S, Saag M, Decker D, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 1991;324: Quinn T. Acute primary HIV infection. JAMA 1997;278: Fox R, Eldred L, Fuchs E, et al. Clinical manifestations of acute infection with human immunodeficiency virus in a cohort of gay men. AIDS 1987;1: Bollinger R, Brookmeyer R, Mehendale S, et al. Risk factors and clinical presentation of acute primary HIV infection in India. JAMA 1997;278: Martin H, Nyange PM, Richardson B, et al. Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of HIV- 1. J Infect Dis 1998;178: Zeger S, Liang K. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42: Simel D, Samsa G, Matchar D. Likelihood ratios for continuous test results making the clinicians job easier or harder? J Clin Epidemiol 1993; 46: Dujardin B, Van den Ende J, Van Gompel A, Unger J, Van der Stuyft P. Likelihood ratios: a real improvement for clinical decision making? Eur J Epidemiol 1994;10: Dorrucci M, Rezza G, Vlahov D, et al. Clinical characteristics and prognostic value of acute retroviral syndrome among injection drug users. AIDS 1995;9: Mellors J, Kingsley L, Rinaldo C, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122: Schacker T, Hughes J, Shea T, Coombs R, Corey L. Biological and virologic characteristics of primary HIV infection. Ann Intern Med 1998;128: Volberding P, Lagakos S, Grimes J, et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. N Engl J Med 1995;333: Kinloch-De Loes S, Hirschel B, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995; 333: Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Foundation. MMWR Morb Mortal Wkly Rep 1998;47(RR-5): Carpenter C, Fischl M, Hammer S. Antiretroviral therapy for HIV infection in 1997 updated recommendations of the International AIDS Society USA Panel. JAMA 1997;277: Zhu T, Mo H, Wang N, et al. Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science 1993;261: Daar E, Moudgil T, Meyer R, Ho D. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 1991;324: Leynaert B, Downs A, de Vincenzi I. Heterosexual transmission of human immunodeficiency virus. Am J Epidemiol 1998;148: Cates W, Chesney M, Cohen M. Primary HIV infection a public health opportunity. Am J Public Health 1997;87: Most J, Zangerle R. Absence of awareness of primary HIV infection. Lancet 1997;349:62.
Vitamin A Supplementation and Genital Shedding of Herpes Simplex Virus among HIV-1 Infected Women: A Randomized Clinical Trial
MAJOR ARTICLE Vitamin A Supplementation and Genital Shedding of Herpes Simplex Virus among HIV-1 Infected Women: A Randomized Clinical Trial Jared M. Baeten, 1,a R. Scott McClelland, 2 Lawrence Corey,
More informationDidactic Series. Primary HIV Infection. Greg Melcher, M.D. UC Davis AETC 8 Nov 2012
Didactic Series Primary HIV Infection Greg Melcher, M.D. UC Davis AETC 8 Nov 2012 ACCREDITATION STATEMENT: University of California, San Diego School of Medicine is accredited by the Accreditation Council
More informationAcute Human Immunodeficiency Virus Infection in Patients Presenting to an Urban Urgent Care Center
MAJOR ARTICLE HIV/AIDS Acute Human Immunodeficiency Virus Infection in Patients Presenting to an Urban Urgent Care Center Jonathan M. Pincus, 1 Sondra S. Crosby, 2 Elena Losina, 3,4 Erin R. King, 2 Colleen
More informationCofactors for the acquisition of HIV-1 among heterosexual men: prospective cohort study of trucking company workers in Kenya
Cofactors for the acquisition of HIV-1 among heterosexual men: prospective cohort study of trucking company workers in Kenya Joel Rakwar, Ludo Lavreys*, Mary Lou Thompson, Denis Jackson*, Job Bwayo, Salim
More informationHuman Herpesvirus 8: Seroprevalence and Correlates in Prostitutes in Mombasa, Kenya
MAJOR ARTICLE Human Herpesvirus 8: Seroprevalence and Correlates in Prostitutes in Mombasa, Kenya Ludo Lavreys, 1,4 Bhavna Chohan, 4 Rhoda Ashley, 2 Barbra A. Richardson, 1,3 Lawrence Corey, 1,3 Kishorchandra
More informationHepadnaviridae family (DNA) Numerous antigenic components Humans are only known host May retain infectivity for more than 7 days at room temperature
Hepatitis B Epidemic jaundice described by Hippocrates in 5th century BC Jaundice reported among recipients of human serum and yellow fever vaccines in 1930s and 1940s Australia antigen described in 1965
More informationTerapia antirretroviral I: Casos especiales
Terapia antirretroviral I: Casos especiales GORDON DICKINSON, M.D. University of Miami There are a number of circumstances in which antiretroviral combination therapy may be administered. Treatment to
More informationImportance of Viral Suppression to Reduce HIV Transmission: Recent Evidence
Importance of Viral Suppression to Reduce HIV Transmission: Recent Evidence Toye Brewer, MD Co-Director, Fogarty International Training Program University of Miami Miller School of Medicine Viral suppression
More informationHIV Lecture. Anucha Apisarnthanarak, MD Division of Infectious Diseases Thammasart University Hospital
HIV Lecture Anucha Apisarnthanarak, MD Division of Infectious Diseases Thammasart University Hospital End-2001 global estimates for children and adults People living with HIV/AIDS New HIV infections in
More informationHIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body
HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body Melissa Badowski, PharmD, BCPS, AAHIVP Clinical Assistant Professor University
More informationHuman Immunodeficiency Virus. Acquired Immune Deficiency Syndrome AIDS
Human Immunodeficiency Virus Acquired Immune Deficiency Syndrome AIDS Sudden outbreak in USA of opportunistic infections and cancers in young men in 1981 Pneumocystis carinii pneumonia (PCP), Kaposi s
More informationFemale-to-Male Infectivity of HIV-1 among Circumcised and Uncircumcised Kenyan Men
MAJOR ARTICLE Female-to-Male Infectivity of HIV-1 among Circumcised and Uncircumcised Kenyan Men Jared M. Baeten, 1,a Barbra A. Richardson, 2,4 Ludo Lavreys, 1 Joel P. Rakwar, 5 Kishorchandra Mandaliya,
More informationManagement of Severe Primary HIV Infection
Management of Severe Primary HIV Infection Martin Fisher Brighton and Sussex University Hospitals Outline What is severe PHI? How frequent is severe PHI? Is this occurring more frequently? Is severe PHI
More informationImportant Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP)
Important Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) For Healthcare Providers About Emtricitabine/Tenofovir Disoproxil
More informationMYTHS OR FACTS OF STI s True or False
Viral STI s MYTHS OR FACTS OF STI s True or False 1. There is no cure for herpes or AIDS. 2. Condoms protect against STI s. 3. If two people are free from STI s and have no other sexual partners, they
More informationBuve, A., H. A. Weiss, et al. (2001). The epidemiology of trichomoniasis in women in four African cities. Aids 15 Suppl 4: S89-96.
Behets, F., J. Andriamiadana, et al. (2001). Sexually transmitted infections and associated socio-demographic and behavioural factors in women seeking primary care suggest Madagascar's vulnerability to
More informationObjectives. HIV in the Trenches HIV Update for the Primary Care Provider, An Overview The HIV Continuum of Care.
1:30 2:30pm HIV Update SPEAKER Gordon Dickinson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Gordon Dickinson, MD, has no financial relationships
More informationSexually Transmitted Infection Treatment and HIV Prevention
Sexually Transmitted Infection Treatment and HIV Prevention Toye Brewer, MD Co-Director, Fogarty International Training Program University of Miami Miller School of Medicine STI Treatment and HIV Prevention.
More informationSummary Guidelines for the Use of Herpes Simplex Virus (HSV) Type 2 Serologies
Summary Guidelines for the Use of Herpes Simplex Virus (HSV) Type 2 Serologies Genital herpes is one of the most prevalent sexually transmitted diseases, affecting more than one in five sexually active
More informationShedding of Human Herpesvirus 8 in Oral and Genital Secretions from HIV-1 Seropositive and Seronegative Kenyan Women
BRIEF REPORT Shedding of Human Herpesvirus 8 in Oral and Genital Secretions from HIV-1 Seropositive and Seronegative Kenyan Women Melanie M. Taylor, 1,a Bhavna Chohan, 5 Ludo Lavreys, 1 Wisal Hassan, 1
More informationTruth THE STORY OF HIV/ CONSEQUENCE. Women's Ministries Department General Conference of Seventh-day Adventists
Truth OR CONSEQUENCE THE STORY OF HIV/ AIDS Women's Ministries Department General Conference of Seventh-day Adventists What is? HIV (Human Immunodeficiency Virus) is a virus that causes AIDS (Acquired
More informationNursing Interventions
Chapter 16 H I Human Immunodeficiency V Virus A Acquired I Immuno D Deficiency S Syndrome Slide 1 Nursing Interventions Duty to treat Health care professionals may not pick and choose their patients Rehabilitation
More informationOR: Steps you can take in the clinic to prevent HIV infections
Implementing Changes to Reduce HIV Incidence: Synergies between Public Health and Primary Care Kevin Ard, MD, MPH Brigham and Women s Hospital, Massachusetts General Hospital, and the Fenway Institute
More information10/17/2015. Chapter 55. Care of the Patient with HIV/AIDS. History of HIV. HIV Modes of Transmission
Chapter 55 Care of the Patient with HIV/AIDS All items and derived items 2015, 2011, 2006 by Mosby, Inc., an imprint of Elsevier Inc. All rights reserved. History of HIV Remains somewhat obscure The earlier
More informationHow is it transferred?
STI s What is a STI? It is a contagious infection that is transferred from one person to another through sexual intercourse or other sexually- related behaviors. How is it transferred? The organisms live
More informationWest Nile Virus in the Region of Peel 2002
HUMAN CASE SURVEILLANCE Introduction Human illness caused by mosquito-borne WNV acquired in Peel occurred for the first time in 2002. In 1999, a Peel resident who had traveled to New York City acquired
More informationImmunodeficiencies HIV/AIDS
Immunodeficiencies HIV/AIDS Immunodeficiencies Due to impaired function of one or more components of the immune or inflammatory responses. Problem may be with: B cells T cells phagocytes or complement
More informationClinical presentations and virologic characteristics of primary human immunodeficiency virus type-1 infection in a university hospital in Taiwan
J Microbiol Immunol Infect 2004;37:271-275 Clinical presentations and virologic characteristics of primary human immunodeficiency virus type-1 infection in a university hospital in Taiwan Hsin-Yun Sun
More informationTargeted screening of at-risk adults for acute HIV-1 infection in sub-saharan Africa
Targeted screening of at-risk adults for acute HIV-1 infection in sub-saharan Africa Eduard J. Sanders a,b,c, Elizabeth Wahome a, Kimberly A. Powers d, Lisa Werner e, Greg Fegan a,b, Ludo Lavreys f, Clement
More informationGuidelines for Implementing Pre-Exposure Prophylaxis For The Prevention of HIV in Youth Peter Havens, MD MS Draft:
Guidelines for Implementing Pre-Exposure Prophylaxis For The Prevention of HIV in Youth Peter Havens, MD MS Draft: 10-2-2015 Clinical studies demonstrate that when a person without HIV infection takes
More informationQuick Study: Sexually Transmitted Infections
Quick Study: Sexually Transmitted Infections Gonorrhea What is it: A bacterial infection of the genitals, anus, or throat. How common: The CDC estimates 820,000 people in the United States get Gonorrhea
More informationWhat is Zika virus? What are the symptoms and complications of Zika virus infection? Are cases expected in Canada?
What is Zika virus? Zika Virus Update for Healthcare Professionals Updated June 22, 2016; italicized text indicates clarification of wording contained in previous versions. Zika virus is a Flavivirus transmitted
More informationProfessor Adrian Mindel
Causes of genital ulceration viruses and others Professor Adrian Mindel University of Sydney VIM 16 th August 2012 Outline Definition Causes Epidemiology Diagnosis Definition of genital ulcer A defect
More informationReducing the Sexual Transmission of Genital Herpes
CLINICAL GUIDELINE Reducing the Sexual Transmission of Genital Herpes Compiled by Adrian Mindel Introduction People diagnosed with genital herpes usually have many questions and concerns, a key one being
More informationBreast-Milk Infectivity in Human Immunodeficiency Virus Type 1 Infected Mothers
MAJOR ARTICLE Breast-Milk Infectivity in Human Immunodeficiency Virus Type 1 Infected Mothers Barbra A. Richardson, 1,3 Grace C. John-Stewart, 2 James P. Hughes, 1 Ruth Nduati, 5 Dorothy Mbori-Ngacha,
More informationEvaluation of Syndromic Algorithms for Managing Sexually Transmitted Infections Among Pregnant Women in Kenya
Evaluation of Syndromic Algorithms for Managing Sexually Transmitted Infections Among Pregnant Women in Kenya Pintye J 1,2, Drake AL 1, Unger JA 3, Matemo D 4, Kinuthia J 4, McClelland RS 1,5,6,7, John-Stewart
More informationMID 36. Cell. HIV Life Cycle. HIV Diagnosis and Pathogenesis. HIV-1 Virion HIV Entry. Life Cycle of HIV HIV Entry. Scott M. Hammer, M.D.
Life Cycle Diagnosis and Pathogenesis Scott M. Hammer, M.D. -1 Virion Entry Life Cycle of Entry -1 virion -1 Virus virion envelope Cell membrane receptor RELEASE OF PROGENY VIRUS REVERSE Co- TRANSCRIPTION
More informationFertility Desires/Management of Serodiscordant HIV + Couples
Fertility Desires/Management of Serodiscordant HIV + Couples William R. Short, MD, MPH Assistant Professor of Medicine Division Of Infectious Diseases Jefferson Medical College of Thomas Jefferson University
More informationDecreased incidence of sexually transmitted diseases among trucking company workers in Kenya: results of a behavioural risk-reduction programme
Decreased incidence of sexually transmitted diseases among trucking company workers in Kenya: results of a behavioural risk-reduction programme Denis J. Jackson*, Joel P. Rakwar,* Barbra A. Richardson,
More informationState of Alabama HIV Surveillance 2013 Annual Report Finalized
State of Alabama HIV Surveillance 2013 Annual Report Finalized Prepared by: Division of STD Prevention and Control HIV Surveillance Branch Contact Person: Allison R. Smith, MPH Allison.Smith@adph.state.al.us
More informationDownloaded from https://academic.oup.com/jid/article-abstract/183/1/23/ by guest on 11 February 2018
23 Early Human Immunodeficiency Virus (HIV) Infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: Risk Behaviors, Symptoms, and Early Plasma and Genital Tract Virus Load Connie
More informationImportant Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. For Healthcare Providers
Important Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication For Healthcare Providers About TRUVADA for a PrEP Indication INDICATION AND PRESCRIBING CONSIDERATIONS TRUVADA,
More informationAssociation between cervical shedding of herpes simplex virus and HIV-1
CONCISE COMMUNICATION Association between cervical shedding of herpes simplex virus and HIV-1 R. Scott McClelland a, Chia C. Wang a, Julie Overbaugh d, Barbra A. Richardson b, Lawrence Corey d, Rhoda L.
More informationEDMA HIV-AIDS TEAM Fact Sheet November 2007
EDMA HIV-AIDS TEAM Fact Sheet November 2007 1. HIV Facts AIDS epidemic update UNAIDS Epidemic Update, November 2007 (1) 760,000 people to be living with HIV in Western and Central Europe in 2007. 31,000
More informationThe how and why of Acute HIV Infection 1. How do we best diagnosis patients with acute HIV?
Acute HIV infection Eric Rosenberg, MD Associate Professor of Pathology Director, Clinical Microbiology Laboratory Massachusetts General Hospital Harvard Medical School The how and why of Acute HIV Infection
More informationEpidemiology Update Hepatitis A
December 2011 Epidemiology Update Hepatitis A Hepatitis A Key Points Between 2000 and 2010, 209 cases of hepatitis A were reported in Hennepin County residents. This represents 30% of the cases reported
More informationDecline of CD3-positive T-cell counts by 6 months of age is associated with rapid disease progression in HIV-1 infected infants
Decline of CD3-positive T-cell counts by 6 months of age is associated with rapid disease progression in HIV-1 infected infants Javier Chinen, Baylor College of Medicine Kirk Easley, Emory University Herman
More informationClinical Infectious Diseases Advance Access published June 16, Age-Old Questions: When to Start Antiretroviral Therapy and in Whom?
Clinical Infectious Diseases Advance Access published June 16, 2015 1 Age-Old Questions: When to Start Antiretroviral Therapy and in Whom? Rochelle P. Walensky, Martin S. Hirsch From the Division of Infectious
More informationDifferences in Clinical Manifestations of Acute and Early HIV-1 Infection between HIV-1 Subtypes in African Women
HIV Clinical Management Differences in Clinical Manifestations of Acute and Early HIV-1 Infection between HIV-1 Subtypes in African Women Journal of the International Association of Providers of AIDS Care
More information958 HIV: The Initial Physician-Patient Encounter Mayo Clin Proc, September 2002, Vol 77 Table 1. Indications for HIV Screening* High-risk behaviors Mu
Mayo Clin Proc, September 2002, Vol 77 HIV: The Initial Physician-Patient Encounter 957 Concise Review for Clinicians Human Immunodeficiency Virus: The Initial Physician-Patient Encounter MARY J. KASTEN,
More informationSex and Sexuality
Sex and Sexuality Sex and Sexuality BEFORE LAUNCHING INTO SOME OF THE SOCIAL PROBLEMS CREATED BY THE CONFLICT BETWEEN OUR SEXUAL NATURE AND SOCIAL CONSTRAINTS ON THE EXPRESSION OF THAT NATURE, IT MIGHT
More informationPopulation attributable fraction of genital inflammation and ulceration in HIV risk among discordant couples, Zambia,
Population attributable fraction of genital inflammation and ulceration in HIV risk among discordant couples, Zambia, 1994-2012 10 th International Workshop on HIV Transmission Kristin M. Wall, PhD kmwall@emory.edu
More informationRon Gray, MBBS, MFCM, MSc Johns Hopkins University. STIs in an International Setting
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationHIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More informationGenital Herpes in the STD Clinic
Genital Herpes in the STD Clinic Christine Johnston, MD, MPH Last Updated: 5/23/2016 uwptc@uw.edu uwptc.org 206-685-9850 Importance of HSV HSV is the leading cause of GUD - HSV is very common HSV-2: 16%
More informationHIV/AIDS Primer for Nurse Practitioners Nursing is Attending to Meaning. Bill Wade R.N June 21,2005.
HIV/AIDS Primer for Nurse Practitioners Nursing is Attending to Meaning Bill Wade R.N June 21,2005. 1 Goals of this presentation Offer minimum content levels to enhance your learning needs around HIV/AIDS
More informationPerformance of Focus, Kalon, and Biokit for the Detection of Herpes Simplex Virus Type
CVI Accepts, published online ahead of print on 28 May 2008 Clin. Vaccine Immunol. doi:10.1128/cvi.00006-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All
More information43. Guidelines on Needle stick Injury
43. Guidelines on Needle stick Injury The following information is abstracted from the South African Department of Health guidelines entitled: Management of Occupational Exposure to the Human Immunodeficiency
More informationHIV Basics: Pathogenesis
HIV Basics: Pathogenesis Michael Saag, MD, FIDSA University of Alabama, Birmingham Director, Center for AIDS Research ACTHIV 2011: A State-of-the-Science Conference for Frontline Health Professionals Learning
More informationHIV Prevention in US Women
HIV Prevention in US Women Sally L. Hodder M.D. Sally L. Hodder MD Professor of Medicine December 1, 2010 24, 2010 Overview Epidemiology of HIV in US women HIV testing Antiretroviral i treatment as HIV
More informationPrEP in the Real World: Clinical Case Studies
PrEP in the Real World: Clinical Case Studies Kevin L. Ard, MD, MPH April 30, 2015 Massachusetts General Hospital, National LGBT Health Education Center Continuing Medical Education Disclosure Program
More informationVirology Introduction. Definitions. Introduction. Structure of virus. Virus transmission. Classification of virus. DNA Virus. RNA Virus. Treatment.
DEVH Virology Introduction Definitions. Introduction. Structure of virus. Virus transmission. Classification of virus. DNA Virus. RNA Virus. Treatment. Definitions Virology: The science which study the
More informationQUANTITATIVE HIV RNA (VIRAL LOAD)
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS QUANTITATIVE HIV RNA (VIRAL LOAD) Policy Number: PDS - 008 Effective Date: October
More informationThe Latest on HIV Testing. Dominika Seidman, MD MAS
The Latest on HIV Testing Dominika Seidman, MD MAS Disclosures none 2 Learning objectives At the conclusion of this session, participants should be able to Define the window periods for various HIV tests
More informationState of Alabama HIV Surveillance 2014 Annual Report
State of Alabama HIV Surveillance 2014 Annual Report Prepared by: Division of STD Prevention and Control HIV Surveillance Branch Contact Person: Richard P. Rogers, MS, MPH richard.rogers@adph.state.al.us
More informationThe Synergy between HIV and other STIs
Training Course in Sexual and Reproductive Health Research 2017 Module: Sexually transmitted infections, HIV/AIDS The Synergy between HIV and other STIs Alberto Matteelli Brescia University Sexual Transmission
More informationABSTRACT Background It is unclear whether there are differences
INITIAL PLASMA HIV-1 RNA LEVELS AND PROGRESSION TO AIDS IN WOMEN AND MEN TIMOTHY R. STERLING, M.D., DAVID VLAHOV, PH.D., JACQUIE ASTEMBORSKI, M.H.S., DONALD R. HOOVER, PH.D., M.P.H., JOSEPH B. MARGOLICK,
More informationDiagnosis and Management of Acute HIV
Diagnosis and Management of Acute HIV A New HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV, this committee
More informationHIV: What Every Clinician Needs to Know ARIZONA STATE ASSOCIATION OF PHYSICIAN ASSISTANTS SPRING CONFERENCE BETTIE COPLAN MARCH 2018
HIV: What Every Clinician Needs to Know ARIZONA STATE ASSOCIATION OF PHYSICIAN ASSISTANTS SPRING CONFERENCE BETTIE COPLAN MARCH 2018 Overview Overview recent trends in HIV incidence in the U.S. HIV screening
More informationAnswers to those burning questions -
Answers to those burning questions - Ann Avery MD Infectious Diseases Physician-MetroHealth Medical Center Assistant Professor- Case Western Reserve University SOM Medical Director -Cleveland Department
More informationUnderstanding the Results of VOICE
CONTACT: Lisa Rossi +1-412- 916-3315 (mobile) or +27-(0)73-323-0087 (through 7 March) rossil@upmc.edu About VOICE Understanding the Results of VOICE VOICE Vaginal and Oral Interventions to Control the
More informationmedical monitoring: clinical monitoring and laboratory tests
medical monitoring: clinical monitoring and laboratory tests Purpose of monitoring Check on the physical, psychological and emotional condition of the patient Detect other treatable conditions Identify
More informationTRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. Training Guide for Healthcare Providers
TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication Training Guide for Healthcare Providers About TRUVADA for a PrEP indication to reduce the risk of sexually acquired HIV-1 infection in high-risk
More informationINTEGRATING HIV INTO PRIMARY CARE
INTEGRATING HIV INTO PRIMARY CARE ADELERO ADEBAJO, MD, MPH, AAHIVS, FACP NO DISCLOSURE 1.2 million people in the United States are living with HIV infection and 1 in 5 are unaware of their infection.
More informationINTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE
Ankamma A,, 2014; Volume 3(5): 510-515 INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE STUDY OF SEROPREVALENCE OF HSV-2 AMONG HIV SEROPOSITIVE INDIVIDUALS AT S.V.R.R.G.G.H TIRUPATI ANKAMMA
More informationHIV/AIDS Today: What you need to know when providing services to individuals with HIV/AIDS (Part One) Presented live August 7, 2018
HIV/AIDS Today: What you need to know when providing services to individuals with HIV/AIDS (Part One) Presented live August 7, 2018 Mary McCarty-Arias, M.A., CRC More than 25 years experience training
More informationNIH Public Access Author Manuscript J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2012 June 11.
NIH Public Access Author Manuscript Published in final edited form as: J Acquir Immune Defic Syndr. 2001 February 1; 26(2): 170 175. Comparison of Techniques for HIV-1 RNA Detection and Quantitation in
More informationClinical Manifestations of HIV
HIV Symptoms Diane Havlir, MD Professor of Medicine and Chief, HIV/AIDS Division University of California, San Francisco (UCSF) WorldMedSchool; July 2, 2013 1 Clinical Manifestations of HIV! Result from
More informationA Summary of Clinical Evidence
A Summary of Clinical Evidence Supporting the use of the Alere Determine HIV-1/2 Ag/Ab Combo Rapid Test to assist in the diagnosis of Human Immunodeficiency Virus (HIV) TAP HERE TO SEE THE PRODUCTS Table
More informationChancroid Table of Contents
Subsection: Chancroid Page 1 of 8 Chancroid Table of Contents Chancroid Fact Sheet Subsection: Chancroid Page 2 of 8 Chancroid (Haemophilus ducreyi) Overview (1,2) For a more complete description of chancroid,
More informationTo provide the guidelines for the management of healthcare workers who have had an occupational exposure to blood and/or body fluids.
TITLE/DESCRIPTION: MANAGEMENT OF OCCUPATIONAL EXPOSURE TO HBV, HCV, and HIV INDEX NUMBER: EFFECTIVE DATE: APPLIES TO: ISSUING AUTHORITY: 01/01/2009 01/01/2013 All GCC Countries GULF COOPERATION COUNCIL
More informationHepatitis B and Hepatitis B Vaccine
Hepatitis B and Epidemiology and Prevention of Vaccine- Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition website at http://www.vaccineinformation.org/photos/index.asp
More informationGENITAL HERPES. 81.1% of HSV-2 infections are asymptomatic or unrecognized. Figure 14 HSV-2 seroprevalence among persons aged years by sex.
GENITAL HERPES Genital herpes is a chronic, lifelong, sexually transmitted disease caused by herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2). HSV-1 typically causes small, painful, fluid-filled,
More information0% 0% 0% Parasite. 2. RNA-virus. RNA-virus
HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe Impact of Sexually Transmitted Diseases(STD) on Women
The Impact of Sexually Transmitted Diseases(STD) on Women GAL Community Symposium AUM September 2, 2011 Agnes Oberkor, MPH, MSN, CRNP, Nurse Practitioner Senior Alabama Department of Public Health STD
More informationNIH Public Access Author Manuscript Clin Infect Dis. Author manuscript; available in PMC 2009 October 1.
NIH Public Access Author Manuscript Published in final edited form as: Clin Infect Dis. 2008 October 1; 47(7): 893 899. doi:10.1086/591534. Normalization of Serum Rapid Plasma Reagin Titer Predicts Normalization
More informationColloque scientifique : L économie de la prévention Analysis of Cost-Effectiveness of HIV Prevention
Colloque scientifique : L économie de la prévention Analysis of Cost-Effectiveness of HIV Prevention Julia Walsh MD, MSc Professor School of Public Health University of California Berkeley Objectives Cost-effectiveness
More informationHEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38
2016 Annual Morbidity Report HEPATITIS C, ACUTE a Rates calculated based on less than 19 cases or events are considered unreliable b Calculated from: CDC. Notice to Readers: Final 2016 Reports of Nationally
More informationT here are an estimated cases of gonorrhoea annually
124 ORIGINAL ARTICLE Gonorrhoea reinfection in heterosexual STD clinic attendees: longitudinal analysis of risks for first reinfection S D Mehta, E J Erbelding, J M Zenilman, A M Rompalo... See end of
More informationSeble G. Kassaye, M.D., M.S. Assistant Professor of Medicine Division of Infectious Diseases and Travel Medicine Georgetown University
Seble G. Kassaye, M.D., M.S. Assistant Professor of Medicine Division of Infectious Diseases and Travel Medicine Georgetown University November 5, 2016 None HIV epidemiology Global U.S. Washington, D.C.
More information2
1 2 3 1. Usinger KM et al. Intrauterine contraception continuation in adolescents and young women: a systematic review. J Pediatr Adolesc Gynecol 2016; 29: 659 67. 2. Kost K et al. Estimates of contraceptive
More informationHIV/AIDS MEASURES GROUP OVERVIEW
2014 PQRS OPTIONS F MEASURES GROUPS: HIV/AIDS MEASURES GROUP OVERVIEW 2014 PQRS MEASURES IN HIV/AIDS MEASURES GROUP: #159. HIV/AIDS: CD4+ Cell Count or CD4+ Percentage Performed #160. HIV/AIDS: Pneumocystis
More informationHPV Epidemiology and Natural History
HPV Epidemiology and Natural History Rachel Winer, PhD, MPH Associate Professor Department of Epidemiology University of Washington School of Public Health rlw@uw.edu Human Papillomavirus (HPV) DNA virus
More informationTrends in Reportable Sexually Transmitted Diseases in the United States, 2007
Trends in Reportable Sexually Transmitted Diseases in the United States, 2007 National Surveillance Data for Chlamydia, Gonorrhea, and Syphilis Sexually transmitted diseases (STDs) remain a major public
More informationNew Brunswick Report on Sexually Transmitted and Blood Borne Infections, 2016
New Brunswick Report on Sexually Transmitted and Blood Borne Infections, 6 Table of Contents. Introduction.... Methodology... 3. Data Limitations.... Definitions used... 3 5. Overview of STBBI epidemiology
More informationJoanne Stekler, MD, MPH Assistant Professor of Medicine Deputy Director, Public Health Seattle & King County HIV/STD Program
NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV Testing Joanne Stekler, MD, MPH Assistant Professor of Medicine Deputy Director, Public Health Seattle & King County HIV/STD Program Presentation prepared
More informationDisclosure. Learning Objectives. Epidemiology. Transmission. Risk of Transmission PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION 50,000.
Disclosure PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION I have no financial interest in and/or affiliation with any external organizations in relation to this CE program. DaleMarie Vaughan, PharmD
More informationA Descriptive Study of Outcomes of Interventions to Prevent Mother to Child Transmission of HIV in Lusaka, Zambia
ORIGINAL PAPER A Descriptive Study of Outcomes of Interventions to Prevent Mother to Child Transmission of HIV in Lusaka, Zambia Chibesa Shichitamba W, National Malaria Control Centre, Lusaka-Zambia ABSTRACT
More informationHormonal Contraception and the Risk of HIV Acquisition
Hormonal Contraception and the Risk of HIV Acquisition Charles Morrison, PhD International Conference on Family Planning Kampala, Uganda November 16, 2009 Hormonal Contraception and HIV About 16 million
More information